Source:http://linkedlifedata.com/resource/pubmed/id/20737169
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
2010-10-4
|
pubmed:abstractText |
Gastric carcinoma (GC) is one of the human cancers in which promoter CpG island hypermethylation is frequently found. CpG island methylator phenotype (CIMP) refers to a subset of GCs which harbor concordant methylation of multiple promoter CpG island loci. However, little is known regarding clinicopathological features of CIMP-positive (CIMP-high) GC. Our study aimed to characterize clinicopathological features of CIMP-high GC. We analyzed 196 cases of GCs for their methylation status in 16 cancer-specific CpG island loci using MethyLight assay and arbitrarily defined CIMP-high GC as those with methylation at 13 or more CpG island loci. With exclusion of microsatellite instability-positive GC and EBV-positive GC from the analysis, CIMP-high GC (n?=?10, 6.7%) demonstrated tendency toward higher cancer stage, infiltrative growth type, poor differentiation, and diffuse or mixed type of Lauren classification. CIMP-high GC showed significantly shortened survival compared with that of CIMP-negative GC. When CIMP-negative GC (methylation at 12 or less) was divided into CIMP-intermediate and CIMP-low (methylation at one or none), CIMP-low exhibited better clinical outcome than CIMP-intermediate. Hypermethylation at 14 CpG island loci or more was closely associated with poor clinical outcome and found to be an independent prognostic factor. Our findings that CIMP-high GCs were featured with characteristic clinicopathological parameters, including poor prognosis are distinct from previous studies. More extensive, large-scaled study is necessary to validate the findings of the present study.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
1432-2307
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:volume |
457
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
415-22
|
pubmed:meshHeading |
pubmed-meshheading:20737169-Adult,
pubmed-meshheading:20737169-Aged,
pubmed-meshheading:20737169-CpG Islands,
pubmed-meshheading:20737169-DNA Methylation,
pubmed-meshheading:20737169-Female,
pubmed-meshheading:20737169-Humans,
pubmed-meshheading:20737169-Male,
pubmed-meshheading:20737169-Middle Aged,
pubmed-meshheading:20737169-Phenotype,
pubmed-meshheading:20737169-Stomach Neoplasms
|
pubmed:year |
2010
|
pubmed:articleTitle |
CpG island hypermethylator phenotype in gastric carcinoma and its clinicopathological features.
|
pubmed:affiliation |
Department of Pathology, National Cancer Center, Goyang, Gyeonggi-do, South Korea.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|